Arcellx announces new positive data for its immagine-1 study in patients with relapsed and/or refractory multiple myeloma

Redwood city, calif.--(business wire)--arcellx, inc. (nasdaq: aclx), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its pivotal phase 2 immagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (rrmm). these data will be presented during an oral presentation at the eha2025 congress in milan.
ACLX Ratings Summary
ACLX Quant Ranking